Mabwell's Nectin-4 ADC Shows Promising Results in Cervical Cancer Trials
Event summary
- Mabwell presented clinical results of its Nectin-4-targeting ADC 9MW2821 at the ESMO Gynaecological Cancers Congress 2026, showing promising therapeutic effects in cervical cancer.
- The Phase I/II study enrolled 55 patients with recurrent or metastatic cervical cancer, with a confirmed objective response rate (cORR) of 32.08% and a disease control rate (DCR) of 81.13%.
- The combination of 9MW2821 with a PD-1 inhibitor showed an objective response rate (ORR) of 76.9% in a Phase Ib/II study, with no new safety signals observed.
- 9MW2821 has obtained FDA Fast Track Designation for three indications, Orphan Drug Designation for one indication, and Breakthrough Therapy Designation from the CDE of NMPA for two indications.
The big picture
Mabwell's presentation at the ESMO Gynaecological Cancers Congress 2026 highlights the growing interest in targeted therapies for cervical cancer. The promising results of 9MW2821, particularly in combination with a PD-1 inhibitor, position Mabwell as a key player in the development of next-generation oncology treatments. The company's ability to navigate regulatory pathways and secure designations from both the FDA and NMPA will be critical in determining the commercial success of 9MW2821.
What we're watching
- Regulatory Progress
- Whether Mabwell can leverage the interim analysis data from its Phase III clinical trials to secure pre-NDA meetings with the National Medical Products Administration.
- Commercialization Strategy
- The pace at which Mabwell can advance 9MW2821 through Phase III trials and bring it to market, given the promising early results.
- Competitive Positioning
- How Mabwell's Nectin-4-targeting ADC will differentiate itself in the crowded oncology market, particularly in cervical cancer and triple-negative breast cancer.
Related topics